Displaying drugs 11776 - 11800 of 12870 in total
SHR-A1904
SHR-A1904 is under investigation in clinical trial NCT04877717 (A Study of SHR-A1904 in Patients With Advanced Solid Cancer).
Investigational
Pemivibart
Pemivibart (Pemgarda) is a half life-extended monoclonal antibody targeting the SARS-CoV-2 spike protein receptor binding domain. It received emergency use authorization (EUA) by the FDA in March 2024 for pre-exposure prophylaxis (PrEP) of COVID-19 in certain high-risk patient populations.
Investigational
rAAV1-CB-hAAT
rAAV1-CB-hAAT is a recombinant adeno-associated virus alpha 1-antitrypsin vector.
Investigational
BVX-001
BVX001 is a a novel, first-in-class CD33/CD7-directed antibody-drug conjugate.
Investigational
MS1901
Investigational
Zamtocabtagene autoleucel
Investigational
Lusvertikimab
Investigational
GXC-301
Investigational
Vudalimab
Vudalimab is under investigation in clinical trial NCT05005728 (Xmab®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-resistant Prostate Cancer).
Investigational
Acapatamab
Acapatamab is under investigation in clinical trial NCT04631601 (Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (Mcrpc)).
Investigational
Socazolimab
Socazolimab is under investigation in clinical trial NCT04878016 (A Study of Carboplatin Plus Etoposide With or Without ZKAB001 (Anti-pd-l1 Antibody) in Patients With ES-SCLC).
Investigational
Rosnilimab
Rosnilimab is under investigation in clinical trial NCT06041269 (A Study of Efficacy and Safety of Rosnilimab in Subjects With Moderate to Severe Rheumatoid Arthritis (RENOIR)).
Investigational
Fianlimab
Fianlimab is under investigation in clinical trial NCT06190951 (A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-pd1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma).
Investigational
Ginisortamab
Ginisortamab is under investigation in clinical trial NCT04393298 (A Study to Assess the Safety, Pharmacokinetics and Anti Tumor Activity of UCB6114 Administered Intravenously to Participants With Advanced Solid Tumors).
Investigational
Zinlirvimab
Zinlirvimab is under investigation in clinical trial NCT03707977 (Dual Bnab Treatment in Children).
Investigational
Zeluvalimab
Zeluvalimab is under investigation in clinical trial NCT04631601 (Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (Mcrpc)).
Investigational
Vobramitamab duocarmazine
Vobramitamab duocarmazine is under investigation in clinical trial NCT05551117 (A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors).
Investigational
Ubamatamab
Ubamatamab is under investigation in clinical trial NCT03564340 (Study of REGN4018 Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers).
Investigational
Visugromab
Visugromab is under investigation in clinical trial NCT06059547 (Neoadjuvant Immunotherapy in Combination With the Anti-gdf-15 Antibody Visugromab (CTL-002) for Treatment of Muscle Invasive Bladder Cancer).
Investigational
Sibeprenlimab
Sibeprenlimab is under investigation in clinical trial NCT05248659 (Phase 2/3 Open-label Trial of Sibeprenlimab in the Treatment of Immunoglobulin a Nephropathy).
Investigational
Frexalimab
Frexalimab is under investigation in clinical trial NCT06141486 (Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis).
Investigational
Licaminlimab
Licaminlimab is under investigation in clinical trial NCT05896670 (Safety and Efficacy of Licaminlimab Ophthalmic Suspension for the Treatment of Dry Eye Disease).
Investigational
Tarcocimab tedromer
Tarcocimab tedromer is under investigation in clinical trial NCT06270836 (A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer Compared With Sham Treatment in Participants With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy (NPDR)).
Investigational
Pulocimab
Pulocimab is under investigation in clinical trial NCT06341335 (A Study of Ak104/placebo Plus Ak109/placebo and Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma).
Investigational
Displaying drugs 11776 - 11800 of 12870 in total